- Title: Subtitle
- Poster: MM-379: MagnetisMM-1: A Study of Elranatamab (PF-06863135), a B-Cell Maturation Antigen (BCMA)-Targeted, CD3-Engaging Bispecific Antibody, for Patients with Relapsed or Refractory Multiple Myeloma (MM)
- Creators
- Moshe Levy - Scott & White HospitalNizar Bahlis - University of CalgaryNoopur Raje - Massachusetts General HospitalCaitlin Costello - University of California, San DiegoBhagirathbhai Dholaria - Vanderbilt UniversityMelhem Solh - Northside HospitalMichael Tomasson - University of IowaHarman Dube - PfizerMichael Damore - PfizerHoi Kei Lon - PfizerCynthia Basu - PfizerAthanasia Skoura - PfizerEdward Chan - PfizerSuzanne Trudel - Princess Margaret Cancer CentreAndrzej Jakubowiak - University of Chicago Medical CenterMichael Chu - Cross Cancer Institute, Edmonton, Alberta, CanadaCristina Gasparetto - Duke UniversityAndrew Dalovisio - Ochsner Health SystemMichael Sebag - McGill UniversityAlexander Lesokhin - Memorial Sloan Kettering Cancer Center
- Resource Type
- Abstract
- Publication Details
- Clinical lymphoma, myeloma and leukemia, Vol.21, pp.S252-S252
- Publisher
- Elsevier Inc
- DOI
- 10.1016/S2152-2650(21)01578-0
- ISSN
- 2152-2650
- eISSN
- 2152-2669
- Language
- English
- Date published
- 09/2021
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Health and Human Physiology; Internal Medicine
- Record Identifier
- 9984363549002771
Abstract
Poster: MM-379: MagnetisMM-1: A Study of Elranatamab (PF-06863135), a B-Cell Maturation Antigen (BCMA)-Targeted, CD3-Engaging Bispecific Antibody, for Patients with Relapsed or Refractory Multiple Myeloma (MM)
Clinical lymphoma, myeloma and leukemia, Vol.21, pp.S252-S252
09/2021
DOI: 10.1016/S2152-2650(21)01578-0
Details
Metrics
26 Record Views